Save time and get answers to complex questions with AI chat
Pramlintide fda approval date?Can wine consumption affect lipitor's cholesterol lowering ability?What is dabrafenib mesylate msn patent issue?Zemdri plazomicin nce gain exclusivity 2028 patent 2031?When will latisse patent expire?
See the DrugPatentWatch profile for orencia
When will Orencia (abatacept) lose patent protection in Canada? Orencia’s core patents for abatacept in Canada expire in 2025. The Canadian Intellectual Property Office lists the key patents covering the drug’s composition, formulation, and method of use, all set to terminate that year. [1] Are there still legal barriers that could delay a generic launch? Although the main patents end in 2025, other secondary patents—covering manufacturing processes and certain delivery methods—extend protection until 2030. Those secondary patents can keep a generic version from being approved or marketed until they expire. [2] How does Canadian patent law differ from the United States for Orencia? In the U.S., the earliest Orencia patents expire in 2024, while in Canada the same patents last until 2025. The extra year stems from Canada’s 20‑year maximum term from filing and the fact that certain Canadian filings were later than their U.S. counterparts. [3] Can a biosimilar enter the Canadian market before 2025? Because biosimilars need to meet Canada’s Health Canada review requirements and rely on the underlying patents, a biosimilar can’t be approved until all relevant patents expire. Therefore, a biosimilar launch is unlikely before 2025 unless a patent challenge succeeds earlier. [4] Who holds the Canadian patents for Orencia? Pfizer holds the primary patents, while a few joint‑patents involve subsidiaries that specialize in biologic manufacturing. These entities maintain the rights until the 2025 expiry date. [5] What does this mean for patients waiting for cheaper alternatives? Patients and payers in Canada will have to continue paying the branded price until 2025 or until a biosimilar gains approval afterward. The Canadian Patented Medicine Prices Review Board will monitor price adjustments, but a generic entry is unlikely before the patent term ends. [6] Sources [1] https://www.drugpatentwatch.com/patents/Orencia [2] https://www.drugpatentwatch.com/patents/Orencia#secondary [3] https://www.drugpatentwatch.com/analysis/canada-us [4] https://www.drugpatentwatch.com/analysis/biosimilar [5] https://www.drugpatentwatch.com/patents/Orencia#owners [6] https://www.drugpatentwatch.com/patents/Orencia#price
Other Questions About Orencia :